Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $33.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.10
• Shares Outstanding: 31,013,876
• 10 Day Avg. Volume: 1,951,986
• 30 Day Avg. Volume: 1,181,896
• PEG Ratio: 0.02
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.24
• P/FCF Ratio: -1.57
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.49
• Enterprise Value/Gross Profit: 4.98
• Enterprise Value/Ebitda: -2.16
• 1Y Price Target: $1.50
• Price Target Upside: 44.23% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: $1.50 ▲(44.23% Upside)

Cosmos Holdings' overall stock score is primarily impacted by its financial performance challenges, including ongoing losses and negative cash flow. Despite strong technical momentum, the lack of earnings and negative P/E ratio weigh heavily on the valuation. Investors should be cautious due to the financial instability, despite the positive technical indicators.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Health Inc. operates as a vertically integrated pharmaceutical company. It offers a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, medical devices, and other products through its distribution channels and an ecommerce marketplace. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece and the United Kingdom; and operates a warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Cosmos Holdings generates revenue through multiple streams, primarily through the sale of its proprietary nutraceutical and pharmaceutical products. The company distributes these products to a wide array of customers, including pharmacies, health food stores, and online platforms. Additionally, Cosmos Holdings leverages strategic partnerships with manufacturers and suppliers to expand its product offerings and market reach. The company also engages in direct-to-consumer sales, enhancing its revenue through e-commerce channels. Moreover, its focus on research and development allows it to introduce new products that meet emerging consumer demands, further contributing to its earnings.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings faces significant financial hurdles with persistent net losses, shrinking revenue, and negative cash flows. While there are signs of reducing debt, the company's financial health remains strained by operational inefficiencies and a heavy reliance on liabilities. Sustainability and profitability improvements are essential to stabilize and enhance financial performance.

Income Statement

Cosmos Holdings' income statement reveals challenges in profitability, with consistent net losses and negative EBIT and EBITDA margins over recent periods. The TTM data shows a slight reduction in revenue, indicating a -1.60% revenue growth rate compared to the previous annual period. Despite some improvement in gross profit margin over the TTM period, the negative net profit margin and declining revenue indicate struggles in operational efficiency and market position.

Balance Sheet

The balance sheet of Cosmos Holdings shows moderate financial stability with a debt-to-equity ratio stabilizing as stockholders' equity increases. However, high total liabilities and low equity ratios reflect potential solvency concerns. The company has reduced total debt significantly over the TTM period, but the equity ratio remains weak, indicating a heavy reliance on liabilities.

Cash Flow

Cosmos Holdings' cash flow statement highlights ongoing liquidity challenges, with negative free cash flow and operating cash flow over recent periods. The TTM shows a negative free cash flow growth rate of approximately 30.05% compared to the previous year, indicating inefficiencies in cash generation. The operating cash flow to net income ratio remains negative, underscoring persistent cash burn issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	55.09M	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	5.42M	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-12.51M	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-15.37M	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	61.84M	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	685.77K	336.25K	3.85M	20.76M	293.18K	851.19K
Total Debt	15.65M	11.82M	12.42M	12.03M	27.12M	32.04M
Total Liabilities	35.60M	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	26.23M	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-5.77M	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-4.49M	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-975.92K	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	6.47M	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Neutral. The current price of 1.04 is below the 20-day moving average (MA) of 1.08, above the 50-day MA of 0.92, and above the 200-day MA of 0.63, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.06 is Neutral, neither overbought nor oversold. The STOCH value of 48.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	54 Neutral	$33.81M	―	-52.69%	―	―	―
BFRI	52 Neutral	$10.56M	―	-531.54%	―	11.20%	63.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$23.00M	―	-60.76%	―	-18.05%	33.87%
TXMD	47 Neutral	$12.10M	―	-1.98%	―	156.93%	92.75%
FLGC	44 Neutral	$13.54M	―	-230.73%	―	-24.10%	38.17%

Cosmos Holdings Corporate Events

Cosmos Holdings Secures $8M Convertible Note Agreement

Cosmos Health Inc. has entered into a Securities Purchase Agreement with an institutional investor, resulting in the issuance of a 9% original issue discount senior secured convertible promissory note worth $8,000,000. This transaction, completed on August 7, 2025, was conducted as a private offering under an exemption from registration. The note, maturing on August 7, 2027, allows for conversion into common stock and includes a beneficial ownership limitation to prevent the purchaser from owning more than 4.99% of the company’s outstanding shares. The note ranks senior to all other company debt, excluding permitted indebtedness.